The largest community of pharma leaders

Insulet Appoints Jim Hollingshead to Board of Directors

ACTON, Mass.–(BUSINESS WIRE)–Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced that Jim Hollingshead, Ph.D., has been appointed to the Company’s Board of Directors, effective immediately. Dr. Hollingshead is President of the Sleep business at ResMed (NYSE: RMD), a pioneer in cloud connected medical devices focused on the treatment of sleep related….

Recent Articles